Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Source: 
Endpoints
snippet: 

In a first, a small runner-up vaccine developer says its own Covid-19 jab has induced “superior neutralizing antibody titer levels” over AstraZeneca’s AZD1222 when pitted head-to-head in a Phase III trial.